Drug Profile
APVO 414
Alternative Names: Anti-PSMA-X-Anti-CD3-ADAPTIR molecule - MorphoSys/Emergent-BioSolutions; APVO-414; ES 414; MOR 209 ES 414; MOR-209/ES-414Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Aptevo Therapeutics; Emergent BioSolutions
- Developer Aptevo Therapeutics; MorphoSys
- Class Antineoplastics; Bispecific antibodies; Proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD3 antigen inhibitors; Cytotoxic T lymphocyte modulators; Glutamate carboxypeptidase II inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 18 Feb 2019 Aptevo Therapeutics completes a phase I trial in Prostate cancer (Hormone refractory, Metastatic disease) in Australia and USA (IV) (NCT02262910)
- 14 Nov 2018 Discontinued - Phase-I for Prostate cancer (Hormone refractory, Metastatic disease) in Australia (IV)
- 14 Nov 2018 Discontinued - Phase-I for Prostate cancer (Hormone refractory, Metastatic disease) in USA (IV)